Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
RESEARCH TOOLSreports
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.51Last Year’s EPS
0.48Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 29, 2025
|% Change Since: -21.04%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance in key products and business segments, alongside improvements in credit ratings, but also highlighted challenges such as the impact of macroeconomic factors and the future decline in Revlimid revenue. Despite these challenges, Teva remains optimistic about its growth strategy and product pipeline.Company Guidance
During the call, Teva Pharmaceutical Industries provided detailed guidance for 2025. The company anticipates revenue growth of 2% to 5%, projecting revenues between $16.8 billion and $17.4 billion, driven by continued momentum in its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, as well as a growing generics business. The adjusted EBITDA is expected to be in the range of $4.5 billion to $5 billion, consistent with 2024 levels. Teva also forecasts a non-GAAP EPS between $2.35 and $2.65. The company plans to maintain a stable gross margin of approximately 53% to 54% and intends to invest about 27% to 28% of revenue into operating expenses to sustain its growth trajectory. Additionally, free cash flow is expected to be between $1.6 billion and $1.9 billion, accounting for higher legal settlement outflows and adjustments in the accounts receivable securitization program.Strong Performance of Key Products
AUSTEDO revenue grew by 34%, UZEDY exceeded its target with $117 million, and AJOVY grew by 18% and reached $0.5 billion in revenue.
Generics Business Growth
The generics business grew by 11%, marking the second consecutive year of growth across all regions.
Improved Credit Ratings
Teva's credit ratings outlook improved with all major rating agencies, reflecting better growth prospects and a stronger balance sheet.
Record Revenue and Earnings Increase
Teva reported $16.5 billion in revenue, a 9% increase, with an adjusted EBITDA of $4.8 billion, also up 9%.
---
TEVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TEVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 29, 2025 | $21.53 | $18.54 | -13.89% |
| Nov 06, 2024 | $18.77 | $17.43 | -7.14% |
| Jul 31, 2024 | $16.41 | $17.43 | +6.22% |
| May 08, 2024 | $13.95 | $15.74 | +12.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Teva Pharmaceutical (TEVA) report earnings?
Teva Pharmaceutical (TEVA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Teva Pharmaceutical (TEVA) earnings time?
Teva Pharmaceutical (TEVA) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TEVA EPS forecast?
TEVA EPS forecast for the fiscal quarter 2025 (Q1) is 0.51.
---
